GERD: Clinical Trials

17 trials for GERD, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed. 17 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 417Completed 17

Follow GERD: new trials by email Literature Review of GERD trials Research Report on GERD

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Obesity on Proton Pump Inhibitors
Lansoprazole, Pantoprazole, Midazolam - Pediatric Obesity, NAFLD
Phase 4CompletedChildren's Mercy Hospital Kansas City762018-07-032026-06-04
Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS
Neobianacid®, Omeprazole 20mg, Neobianacid® placebo - GERD, EPS
Phase 4CompletedAboca Spa Societa' Agricola2752017-09-122022-11-21
An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan
Dexlansoprazole 60 MG - GERD, Proton Pump Inhibitor
Phase 4CompletedAmerican University of Beirut Medical Center332017-02-272017-09-15
Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases
OMEZ 40, OMEZ 80 - GERD
Phase 4CompletedDr. Reddy's Laboratories Limited1202013-01-012016-10-04
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
esomeprazole 20 mg - Gastroesophageal Reflux Disease, GERD
Phase 4CompletedAstraZeneca1072011-08-012013-02-21
Does Omeprazole Decrease Intestinal Calcium Absorption?
Omeprazole - Osteoporosis, Achlorhydria
Phase 4CompletedUniversity of Wisconsin, Madison232008-01-012013-02-15
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
esomeprazole (Nexium®), Xolaam® - GERD
Phase 4CompletedAstraZeneca30292007-03-012012-12-11
Nexium RESPONSE Trial
Esomeprazole - GERD
Phase 4CompletedAstraZeneca10002006-05-012009-01-26
Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD
Antacids - GERD
Phase 4CompletedDigestive & Liver Disease Specialists502005-10-012009-02-25
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
Esomeprazole - GERD
Phase 4CompletedAstraZeneca3502005-10-012009-03-06
The Utility of Nexium in Chronic Cough and Reflux Disease
Esomeprazole, Placebo - Cough, GERD
Phase 4CompletedUniversity of North Carolina, Chapel Hill402005-09-012012-01-10
Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)
Pantoprazole - Gastroesophageal Reflux, GERD
Phase 4CompletedTakeda3002005-08-012012-05-07
CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing
rabeprazole - GERD
Phase 4CompletedNational Taiwan University Hospital2002005-06-012012-12-03
Sleep Disorders and Gastroesophageal Reflux Disease (GERD)
Rabeprazole - Insomnia, GERD
Phase 4CompletedUniversity of North Carolina202004-09-012007-04-27
PPI Test in GP Patients
Esomeprazole, Ambulatory 24-hour esophageal pH-monitoring - GERD
Phase 4CompletedAstraZeneca1002003-01-012007-08-17
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Esomeprazole - GERD
Phase 4CompletedAstraZeneca602002-09-012011-01-25
Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
Esomeprazole - GERD
Phase 4CompletedAstraZeneca602002-08-012011-01-25

Narrower conditions

Gastroesophageal Reflux (17)  ·  Heartburn (2)  ·  Achlorhydria (1)  ·  Cough (1)  ·  Esophagitis, Peptic (1)  ·  Hip Fractures (1)  ·  Non-alcoholic Fatty Liver Disease (1)  ·  Osteoporosis (1)  ·  Parasomnias (1)  ·  Pediatric Obesity (1)  ·  Sleep Initiation and Maintenance Disorders (1)

Broader conditions

Deglutition Disorders (17)  ·  Digestive System Diseases (17)  ·  Esophageal Diseases (17)  ·  Esophageal Motility Disorders (17)  ·  Gastrointestinal Diseases (17)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Signs and Symptoms (4)  ·  Nutritional and Metabolic Diseases (2)  ·  Signs and Symptoms, Digestive (2)  ·  Stomach Diseases (2)  ·  Acid-Base Imbalance (1)  ·  Body Weight (1)  ·  Bone Diseases (1)  ·  Bone Diseases, Metabolic (1)  ·  Duodenal Diseases (1)

Interventions

Esomeprazole (8)  ·  Omeprazole (3)  ·  Pantoprazole (2)  ·  Rabeprazole (2)  ·  Ambulatory Care Facilities (1)  ·  Antacids (1)  ·  Dexlansoprazole (1)  ·  Lansoprazole (1)  ·  Midazolam (1)

Sponsors

AstraZeneca (7)  ·  Aboca Spa Societa' Agricola (1)  ·  American University of Beirut Medical Center (1)  ·  Children's Mercy Hospital Kansas City (1)  ·  Digestive & Liver Disease Specialists (1)  ·  Dr. Reddy's Laboratories Limited (1)  ·  National Taiwan University Hospital (1)  ·  Takeda (1)  ·  University of North Carolina (1)  ·  University of North Carolina, Chapel Hill (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (6)  ·  Denmark (1)  ·  France (1)  ·  Italy (1)  ·  Lebanon (1)  ·  Netherlands (1)  ·  Taiwan (1)  ·  United Kingdom (1)

Top investigators

Nicholas Shaheen, MD, MPH (2)  ·  David A Johnson, MD (1)  ·  Karen E Hansen, MD (1)  ·  Kathryn Kyler, MD, MS (1)  ·  Makiko Abe (1)  ·  Masataka Date (1)  ·  Ming-Shiang Wu, PHD (1)  ·  Paula Fernstrom (1)  ·  Stig Waldorff, MD (1)  ·  V.D Pasechnikov, MD (1)  ·  Villy Meineche Schmidt, MD (1)

Results publications

PMID 19601705, PMID 20578215, PMID 21083590, PMID 21083673, PMID 21347742, PMID 22759841, PMID 30625462, PMID 37307528, PMID 42226497

NIH funding

K23DK115827 (1)